EGFR and non-small cell lung carcinoma: Based on our findings that both CTLA4 and PD‐L1 are expressed at higher levels in EGFR wild‐type or EGFR activating mutations NSCLC cells (Figure 2A), we focused on determining the EGFR activation status.